Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content
search

Lymphoma Canada is preparing submissions for the pan-Canadian Oncology Drug Review (pCODR) for two upcoming drug reviews for PTCL:

1. Pralatrexate (Folotyn) for relapsed or refractory PTCL


2. Belinostat (Beleodaq) for relapsed or refractory PTCL

If you have or had Peripheral T-Cell Lymphoma (PTCL), you can help by completing our survey.

The survey provides us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

You do not need to live in Canada to complete this survey.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

The survey will be open until midnight Pacific Time on Friday, June 8th, and should only take 15 minutes of your time.

You may access the survey by clicking the appropriate link below.

Survey for those WITH pralatrexate (Folotyn) OR belinostat (Beleodaq) Experience

PTCL Patient Survey for those WITHOUT pralatrexate OR belinostat Experience

Please share and help us spread the word.

Thank you for your support.

laurad

Close Menu